Philip Sin - Head of Capital Markets and Corporate Development - BELIEF BIOMED

Mr. Sin is currently Head of Capital Markets and Corporate Development at Belief BioMed Group, a clinical stage biotechnology company based in Shanghai that is focused on gene therapy R&D with a therapeutic pipeline covering rare diseases such as hemophilia as well as age-related degenerative diseases such as Parkinson Diseases and Arthritis. Previously, he was a seasoned finance executive with 20+ years of experience in investment banking with several international firms.

Philip is a Magna cum Laude graduate of Dartmouth College.